Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa

NCT01975441 is registered in ClinicalTrials.gov with University Hospitals Cleveland Medical Center as lead sponsor.

NCT NCT01975441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01975441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa
Lead sponsor
University Hospitals Cleveland Medical Center
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2014
Completion date
June 30, 2018
Enrollment
182 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphatic filariasis